Heparin-platelet factor 4 antibodies in intensive care patients: An observational seroprevalence study

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 2, 2010, Pages 142-148

  Levine, Robert L ^a,b   Hergenroeder, Georgene W ^a   Francis, John L ^c   Miller, Charles C ^a   Hursting, Marcie J ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c FLORIDA HOSPITAL   (United States)

^d NONE

Author keywords

Antibody; Heparin; Heparin induced thrombocytopenia; Platelet factor 4; Prevalence

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; ANTIBODY; ANTICOAGULANT AGENT; THROMBOCYTE FACTOR 4;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPTICAL DENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROPREVALENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS; APACHE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; IMMUNOLOGY; INTENSIVE CARE; LENGTH OF STAY; MIDDLE AGED; MORTALITY; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME; UNITED STATES;

ANTIBODIES; ANTICOAGULANTS; APACHE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET FACTOR 4; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; TEXAS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957937073     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0425-0     Document Type: Article

References (34)

1. Levy JH, Hursting MJ (2007) Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol Oncol Clin North Am 21:65-88
2. Hirsh J, Heddle N, Kelton JG (2004) Treatment of heparininduced thrombocytopenia: a critical review. Arch Intern Med 164:361-369
3. Warkentin TE, Greinacher A, Koster A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:340S-380S
4. Keeling D, Davidson S, Watson H (2006) The management of heparin-induced thrombocytopenia. Br J Haematol 133:259-269
5. Mattioli AV, Bonetti L, Sternieri S et al (2000) Heparininduced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 1:39-42
6. Williams RT, Damaraju LV, Mascelli MA et al (2003) Antiplatelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107:2307-2312
7. Calaitges JG, Liem TK, Spadone D et al (1999) The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 29:779-785
8. Bennett-Guerrero E, Slaughter TF, White WD et al (2005) Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130:1567-1572
9. Kress DC, Aronson S, McDonald ML et al (2007) Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 83:1737-1743
10. Greinacher A, Eichler P, Lietz T et al (2005) Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106:2921-2922
11. Pena de la Vega L, Miller RS, Benda MM et al (2005) Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80:995-1000
12. Risch L, Fischer JE, Schmugge M et al (2003) Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia. Blood Coagul Fibrinolysis 14:113-116
13. Mascelli MA, Deliargyris EN, Damaraju LV et al (2004) Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis 18:171-175
14. Francis JL (2004) A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 30:359-368
15. Warkentin TE, Sheppard JI, Horsewood P et al (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703-1708
16. Everett BM, Yeh R, Foo SY et al (2007) The prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 83:592-597
17. Napolitano LM, Warkentin TE, Al Mahameed A et al (2006) Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med 34:2898-2911
18. Shalansky SJ, Verma AK, Levine M et al (2002) Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 22:803-813
19. Verma AK, Levine M, Shalanasky SJ et al (2003) Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 23:745-753
20. Selleng K, Warkentin TE, Greinacher A (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35:1165-1176
21. Crowther MA, Cook DJ, Meade MO et al (2005) Thrombocytopenia in medical surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 20:348-353
22. Hourigan LA, Walters DL, Keck SA et al (2002) Heparininduced thrombocytopenia: a common complication in cardiac transplant recipients. J Heart Lung Transplant 21:1283-1289
23. Schmugge M, Risch L, Huber AR et al (2002) Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 109: E10-E14
24. Gettings EM, Brush KA, Van Cott EM et al (2006) Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study. Crit Care 10: R161
25. Scott JR, Klein MB, Gernsheimer T et al (2007) Arterial and venous complications of heparin-induced thrombocytopenia in burn patients. J Burn Care Res 28:71-75
26. Zwicker JI, Uhl L, Huang WY et al (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133-2137
27. Francis JL, Drexler A, Duncan MK et al (2007) Heparin-platelet factor 4 antibodies in patients presenting to the ED with thrombosis. Am J Emerg Med 25:279-284
28. Dattalo P (2008) Determining sample size: balancing power, precision, and practicality. Oxford University Press, New York, NY
29. Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:454S-545S (Pubitemid 351892971)
30. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:381S-453S
31. Mullen MP, Wessel DL, Thomas KC et al (2008) The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 107:371-378
32. Arepally GM, Hursting MJ (2008) Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis 26:55-61
33. Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037-1043
34. Warkentin TE, Makris M, Jay RM et al (2008) A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 121:632-636